Loading company
Maze Therapeutics, Inc.
MAZE · Nasdaq · ·
Next earnings: November 5, 2026
$27.02+0.5%Sep 29 close
- 1M
- -1.5%
- 6M
- -6.9%
- 1Y
- +4.2%
MAZE · Nasdaq · ·
Next earnings: November 5, 2026
$27.02+0.5%Sep 29 close
Maze Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toSep 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $2.5M | -100.00% |
| Profit | -$44.7M | -$33.7M | -32.80% |
| Profit per share | -$0.76 | -$0.77 | +1.30% |
| Free Cash Flow | -$15.2M | -$30.4M | +50.21% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in 2027, and continued strong enrollment in the Phase 2 HORIZON trial of MZE829 across three cohorts with additional data on track for 10-15 patients per cohort in late 2026 or early 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Maze Therapeutics, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Maze Therapeutics, Inc. has no earnings call transcript available.